Shares of Moderna surged into Monday pre-market at $58.20, extending a scorching run that began last week with a ~24% gain from May 5 to today. The catalyst: a twin announcement on May 8 pairing early-stage hantavirus vaccine work with landmark flu vaccine data, reigniting a debate over whether Moderna's mRNA platform can generate enough new revenue to replace its vanishing COVID windfall.
A Cruise Ship Outbreak Handed Moderna a Publicity Windfall
Moderna said it's researching vaccines to protect against hantaviruses, even as public health experts downplay the risk the deadly pathogen aboard a cruise ship could become a significant threat.
The effort is still preclinical, meaning it has not entered human testing and is not part of any approved or planned vaccination program.
The stock surged approximately 14% during Friday's trading session — a huge move for what amounts to lab-stage science with no clear revenue timeline. Investors are pricing in potential, not product.
The Flu Vaccine Is the Real Money Story
A trial of nearly 40,703 participants showed Moderna's mRNA flu shot cut illness by 26.6% compared to a standard-dose vaccine in adults 50 and older.
The FDA is expected to decide on the mRNA flu shot by August 5. The global flu vaccine market tops $7 billion annually. This gives Moderna a clearer entry point into a very large seasonal market where Sanofi, GSK, and Pfizer already compete. An approval would be Moderna's first major non-COVID commercial product in the U.S.
The Financial Reality Check Is Sobering
Q1 2026 sales of $389M show re-acceleration, but profitability is deeply negative, with EBIT margin around –140% and Q1 free cash flow of –$692M.
The company holds $5.2 billion in cash and investments , giving it runway — but the burn rate is fierce. The median analyst price target sits at just $30 , roughly half the current price.
Insiders Aren't Buying Their Own Story
Of recent insider trades, zero have been purchases and four have been sales, including the president selling 160,009 shares for an estimated $7.8 million.
In the past three months, insiders have sold $8.8 million worth of shares with no purchases reported.
The hantavirus headlines are sizzle; the flu approval decision in August is steak. Until Moderna proves it can turn pipeline progress into profits, this rally rides on hope more than math.